Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 1 14Phase 1/2 3Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 19Active not recruiting 9Recruiting 5Withdrawn 2Unknown 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Terminated × ibrutinib × Clear all
NCT02703272 2022-12-02

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Janssen Research & Development, LLC

Phase 3 Terminated
72 enrolled 36 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡